Cerebral aneurysm future or investigational therapies: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
 
Line 2: Line 2:
__NOTOC__
__NOTOC__
{{Cerebral aneurysm}}
{{Cerebral aneurysm}}
{{CMG}} ;{{AE}} {{Anika Zahoor M.D}}
{{CMG}} ;{{AE}} {{AnikaZ}}


== Overview: ==
== Overview: ==

Latest revision as of 04:15, 17 June 2022


Cerebral aneurysm Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Cerebral aneurysm from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Cerebral aneurysm future or investigational therapies On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Cerebral aneurysm future or investigational therapies

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Cerebral aneurysm future or investigational therapies

CDC on Cerebral aneurysm future or investigational therapies

Cerebral aneurysm future or investigational therapies in the news

Blogs on Cerebral aneurysm future or investigational therapies

Directions to Hospitals Treating Cerebral aneurysm

Risk calculators and risk factors for Cerebral aneurysm future or investigational therapies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ;Associate Editor(s)-in-Chief: Anika Zahoor M.D.[2]

Overview:

For future, researchers are currently hitting two main therapies cell & drug therapy

Investigational Therapies

Cerebral aneurysm Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Cerebral aneurysm from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Cerebral aneurysm future or investigational therapies On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Cerebral aneurysm future or investigational therapies

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Cerebral aneurysm future or investigational therapies

CDC on Cerebral aneurysm future or investigational therapies

Cerebral aneurysm future or investigational therapies in the news

Blogs on Cerebral aneurysm future or investigational therapies

Directions to Hospitals Treating Cerebral aneurysm

Risk calculators and risk factors for Cerebral aneurysm future or investigational therapies

In order to get cure from Cerebral Aneurysm, the more focus should be on reconstruction of vascular wall with normal endothelialization.

Currently, there are two main classes of pharmacology, used for this purpose.

Cell Therapies:

  • Endothelial Progenitor cells (EPCs)
  • Mesenchymal stem cells (MSCs)
  • Vascular smooth muscle cells (VSMs)
  • Fibroblasts

Drug Therapies:

  • MCP-1 Inhibitors
  • ACE inhibitors
  • TNF-alpha Inhibitors

Future Perspectives:

The Subarachnoid Hemorrhage is consider as a major cause of Cerebral Aneurysm. The main goal for management of cerebral aneurysm is prevention of rupture or re-rupture.

The main management for CA is currently surgical procedures which only modify morphological aspects of aneurysm and cannot completely prevent from re-rupture.

Therefore, it is necessary to develop more effective and less risky treatments that are also fall in the line of cost-effectiveness.

References

  1. Aoki T, Nozaki K. Preemptive Medicine for Cerebral Aneurysms. Neurol Med Chir (Tokyo). 2016 Sep 15;56(9):552-68. doi: 10.2176/nmc.st.2016-0063. Epub 2016 Apr 6. PMID: 27053328; PMCID: PMC5027238.